France Clinical Nutrition for Chronic Kidney Diseases Market Analysis

France Clinical Nutrition for Chronic Kidney Diseases Market Executive Summary

France Clinical Nutrition for Chronic Kidney Diseases Market was valued at $43.20 Mn in 2023 and is predicted to grow at a CAGR of 5.03% from 2023 to 2030, to $60.90 Mn by 2030. 

Chronic kidney disease (CKD) is a gradual loss of kidney function over at least three months, often progressing silently due to the absence of early symptoms. The main causes include diabetes and high blood pressure, though family history and other conditions also contribute. As CKD advances through stages, it may necessitate dialysis or a kidney transplant and is associated with increased risks of heart disease, stroke, and bone issues. Management focuses on slowing disease progression, symptom management, and preventing complications through dietary changes, medications, and blood pressure control. Key dietary adjustments include moderating protein intake, managing fluid levels, controlling electrolytes like sodium, potassium, and phosphorus, and ensuring sufficient calorie intake to avoid malnutrition. Early detection and screening are crucial for those at risk.

In France, Estimates using the RENALGO-EXPERT algorithm based on healthcare consumption indicate a prevalence ranging from 8.1% to 10.5% in the French National Health claims database (SNDS) between 2018 and 2021. However, relying solely on health claims data may overlook undiagnosed cases or those with early-stage CKD and stable glomerular filtration rate (GFR). Anemia is prevalent among CKD patients, affecting a substantial proportion of the non-dialysis-dependent CKD population.

The market therefore is driven by significant factors like rising CKD prevalence, aging populations, and technology advancements. However, the scarcity of qualified dietitians, the high cost of treatment, evolving reimbursement landscape restrict the growth and potential of the market.

Prominent players in this field are Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

Market Dynamics

Market Growth Drivers

Rising CKD Prevalence: France faces a substantial burden of chronic kidney disease (CKD), largely driven by prevalent conditions such as diabetes and hypertension. This creates a considerable need for specialized nutritional solutions to address these health issues.

Aging Population: France's aging population, with 14.14 Mn people aged 65 years or older in 2023 (21% of the population), faces increased susceptibility to chronic kidney disease (CKD) due to age-related declines in kidney function, hypertension, and diabetes. This underscores the demand for medical nutrition solutions tailored to manage CKD among older adults, emphasizing the need for targeted healthcare strategies.

Technological Advancements: French healthcare embraces innovation. The development of tele-nutrition services can improve access to consultations with qualified dietitians for CKD patients, particularly in remote areas. Additionally, advancements in product formulation can lead to more palatable and convenient CKD nutritional options.

Market Restraints

Scarcity of Qualified Dietitians: France faces challenges in the availability of qualified dietitians with specialized expertise in CKD nutrition. This scarcity limits the accessibility of tailored nutritional guidance for CKD patients, hindering their ability to receive personalized care and dietary management.

High Cost of Treatment: The French healthcare system faces pressure to control costs. While reimbursement exists, ensuring the cost-effectiveness of CKD nutritional interventions will be crucial for sustained market growth.

Evolving Reimbursement Landscape: Ongoing healthcare reforms in France introduce uncertainty regarding the future coverage of CKD-specific clinical nutrition products and consultations. This uncertainty creates barriers for patients who rely on these interventions, potentially affecting their access to essential care and support.

Regulatory Landscape and Reimbursement Scenario

France maintains a robust regulatory framework overseen by key bodies like the Direction Générale de la Santé (DGS) and the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). These entities regulate clinical nutrition for chronic kidney disease (CKD), ensuring products meet stringent safety, efficacy, and quality standards. The French Food Code and EU regulations further mandate precise labeling, composition, and safety protocols for foodstuffs, including specialized dietary products for CKD management. This framework promotes consistency and safety across the market, supporting the availability of reliable nutritional solutions tailored to CKD patients' specific needs.

Regarding reimbursement, France's social security system plays a pivotal role in funding CKD management, covering costs associated with medical consultations and prescribed CKD nutritional products. The reimbursement level varies based on the product and the patient's insurance plan. Additionally, complementary health insurance plans are common among French citizens, providing supplementary coverage for consultations with nutritionists and certain CKD nutritional products not fully reimbursed by the social security system. This dual reimbursement approach ensures that CKD patients have access to essential nutritional support and healthcare services, contributing to comprehensive management and improved quality of life.

Competitive Landscape

Key Players

Here are some of the major key players in the France Clinical Nutrition for Chronic Kidney Diseases Market

• Abbott Nutrition
• Pfizer Inc.
• Bayer AG
• Nestlé Health Science
• Otsuka Pharmaceutical
• Mead Johnson & Company, LLC
• Danone S.A.
• Victus, Inc.
• B. Braun Melsungen AG
• Fresenius Kabi AG